Early approval pathways for drugs often result in access accompanied by a persistent lack of evidence of benefit, experts say.
Expert says “we’ve taken a step back” over the past few months in embracing DCTs.
Technology can significantly enhance clinical trial productivity and reach, “but it can get messy” if it’s not handled properly before, during, and after implementation.
Experts say now is the time to invest in research to combat the spread of misinformation before the next science crisis.
“We’re building the plane while it’s flying.” Ready or not, patient-centric trials fueled by technology and new best practices are here to stay.